Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its novel Nectin-4 targeting ADC (R&D code: 9MW2821) has received IND approval for two clinical ...

and the cell experience and capacity are improved as well. After the High-Speed Railway Dedicated Network Enhancement feature is enabled for the Shanghai-Kunming Railway, the access success rate ...

The Global Battery Alliance (GBA) today successfully unveiled the results of the 2024 Battery Passport pilots during the Annual General Meeting, hosted in Shanghai and Ningde. Ten consortia, led by ...

SHANGHAI, China & JERSEY CITY ... by the NMPA for the treatment of MSI-H solid tumours, squamous non-small cell lung cancer (sqNSCLC) and extensive-stage small cell lung cancer (ES-SCLC), and ...

Elon Musk's good standing with Donald Trump may be good news for Tesla, but not necessarily for EV makers in general.

HCW Biologics entered into License, Research and Co-Development Agreement with WY Biotech for one of its new proprietary preclinical molecules HCW Biologics to receive upfront payment of $7 million ...

Findings could point to new ways to treat RAS-driven cancers BETHESDA, Md., Nov. 12, 2024 /PRNewswire/ -- Researchers at the National Inst ...

Cash and Cash Equivalents: As of September 30, 2024, Senti Bio held cash and cash equivalents of $10.5 million. Subsequent to quarter-end, the Company received $2.5 million, the second tranche of an ...

DALLAS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical ...

For more information, please visit www.immunovia.com PR Newswire SHANGHAI, Nov. 11, 2024 – The MANEUVER study ... Safety and Promising Clinical Activity of TAC01-CLDN18.2 Cell Therapy in Patients with ...